Adrenocortical carcinoma. Surg Oncol Clin N Am 2006 Jul;15(3):535-53
Date
08/03/2006Pubmed ID
16882496DOI
10.1016/j.soc.2006.05.005Scopus ID
2-s2.0-33746378196 (requires institutional sign-in at Scopus site) 25 CitationsAbstract
ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival. Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.
Author List
Rodgers SE, Evans DB, Lee JE, Perrier NDAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenal Cortex NeoplasmsAdrenocortical Carcinoma
Beckwith-Wiedemann Syndrome
Biopsy, Needle
Humans
Hydrocortisone
Insulin-Like Growth Factor II
Magnetic Resonance Imaging
Neoplasm Staging
Proteins
